Results of a meta-analysis showed that all biologic agents were superior to placebo for improving short-term outcomes in moderate to severe plaque psoriasis.

HealthDay News — Severe psoriasis, nail pitting, and the use of retinoids were identified as possible risk factors for development of psoriatic arthritis (PsA) among patients with psoriasis, according ...

Copenhagen University Hospital–Herlev and Gentofte led a nationwide registry study that the authors claim shows a "pattern ...

Please provide your email address to receive an email when new articles are posted on . The proportion of deucravacitinib-treated patients that reported no quality-of-life impact increased from 0% at ...

Patients with moderate to severe psoriasis may benefit from weekend cyclosporine treatment (WCT) as a maintenance therapy, according to one study. The use of weekend cyclosporine treatment (WCT) was ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Tildrakizumab showed significant clinical improvements, with 97.1% achieving Psoriasis Area Severity Index 75 (PASI75) and 82.9% reporting minimal impairment by week 28. The study involved 62 patients ...

An 18-year-old woman presents with a 7-year history of moderate to severe chronic plaque psoriasis involving her scalp, trunk, bilateral upper and lower extremities, and nails. Her chief complaint was ...

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...

ATLANTA, Sept. 17, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced three- and four-year data from across the open-label extension (OLE) Phase 3 trials for BIMZELX® ...

Otezla (apremilast) is an oral tablet commonly used to treat plaque psoriasis in adults and children. Plaque psoriasis is an inflammatory skin condition that causes itchy, painful patches on the skin.

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...